Классификация псориатического артрита коротаева

1. Olivieri I, Padula A, D’Angelo S, Cutro MS. Psoriatic arthritis sine psoriasis. J Rheumatol. 2009;Suppl 83:28–9.

2. Mease PJ. Psoriatic arthritis: update on pathophysiology, assessement and management Ann Rheum Dis. 2011;70 (Suppl):77–84. DOI: https://dx.doi.org/10.1136/ard.2010.140582.

3. Love TJ, Zhu Y, Zhang Y, et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis. 2012;71:1273–7. DOI: https://dx.doi.org/10.1136/annrheumdis- 2012-201299.

4. Moll JMH, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3:55–78. DOI: https://dx.doi.org/10.1016/0049-0172(73)90035-8.

5. Коротаева ТВ. Псориатический артрит: клиника, диагностика, патогенез, лечение, маркеры кардиоваскулярного риска. Под ред. Е.Л. Насонова. Москва: НПО «Медиа-Графика»; 2013. 309 с. [Korotaeva TV. Psoriaticheskii artrit: klinika, diagnostika, patogenez, lechenie, markery kardiovaskulyarnogo riska [Psoriatic arthritis: clinic, diagnostics, pathogenesis, treatment, markers of cardiovascular risk]. Nasonov EL, editor. Moscow: NPO «Media-Grafika»; 2013. 309 p.]

6. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl 2):14–7.

7. Chandran V, Barrett J, Schentag NC, et al. Axial Psoriatic Arthritis: update on a longterm prospective study. J Rheumatol. 2009;36;2744–50. DOI: https://dx.doi.org/10.3899/jrheum.090412.

8. Taylor WJ, Gladman DD, Helliwell PS, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–73. DOI: https://dx.doi.org/10.1002/art.21972.

9. Sieper J, van der Heijde D, Landewe R, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis International Society (ASAS). Ann Rheum Dis. 2009;68:784–8. DOI: https://dx.doi.org/10.1136/ard.2008.101501.

10. Kane D, Pathare S. Early psoriatic arthritis. Rheum Dis Clin North Am. 2005;31(4):641–57. DOI: https://dx.doi.org/10.1016/j.rdc.2005.07.009.

11. Qureshi AA, Husni ME, Mody E. Psoriatic arthritis and psoriasis: need for a multidisciplinary approach. Semin Cutan Med Surg. 2005;24:46–51. DOI: https://dx.doi.org/10.1016/j.sder.2005.01.006.

12. Prey S, Paul C, Bronsard V, et al. Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24(Suppl 2):31–5. DOI: https://dx.doi.org/10.1111/j.1468-3083.2009.03565.x.

13. Gottlieb A, Korman N, Gordon K, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851–64. DOI: https://dx.doi.org/10.1016/j.jaad.2008.02.040.

14. Mease PJ. Assessing the impact of psoriatic arthritis on patient function and quality of life: lessons learned from other rheumatologic conditions. Semin Arthritis Rheum. 2009;38:320–35. DOI: https://dx.doi.org/10.1016/j.semarthrit.2008.01.003.

15. Raychaudhuri SK, Chatterjee S, Nguyen C, et al. Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord. 2010;8:331–4. DOI: https://dx.doi.org/10.1089/met.2009.0124.

16. Li W-Q, Han J-L, Chan TA. Psoriasis and psoriatic arthritis and increased risk of incedent Crohn’s disease in US women. Ann Rheum Dis. 2013;72:1200–5. DOI: https://dx.doi.org/10.1136/annrheumdis-2012-202143.

17. Gossec L, Smolen J, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71(1):4–12. DOI: https://dx.doi.org/10.1136/annrheumdis-2011-200350.

18. Buckley C, Cavill C, Taylor G, et al. Mortality in psoriatic arthritis – a single-center study from the UK. J Rheumatol. 2010;37:2141–4. DOI: https://dx.doi.org/10.3899/jrheum.100034.

19. Tam LS, Tomlinson B, Chu TT, et al. Cardiovascular risk proile of patients with psoriatic arthritis compared to controls – the role of inlammation. Rheumatology (Oxford). 2008;47:718–23. DOI: https://dx.doi.org/10.1093/rheumatology/ken090.

20. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–41. DOI: https://dx.doi.org/10.1001/jama.296.14.1735.

21. Lin HW, Wang KH, Lin HC. Increased risk of acute myocardial infarction in patients with psoriasis: a 5-year population-based study in Taiwan. J Am Acad Dermatol. 2011;64(3):495–501. DOI: https://dx.doi.org/10.1016/j.jaad.2010.01.050.

22. Bhole VM, Choi HK, Burns LC, et al. Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology (Oxford). 2012;51:552–6. DOI: https://dx.doi.org/10.1093/rheumatology/ker349.

23. Gisondi P, Del Giglio M, Di Francesco V, et al. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr. 2008;88:1242–7.

24. Scottish Intercollegiate Guidelines Network (SIGN) publication no 121. Diagnosis and management of psoriasis and psoriatic arthrits in adult: a national clinical guideline. October 2010. Available from: https://www.sign.ac.uk

25. Mease PJ. Assessment tools in psoriatic arthritis. J Rheumatol. 2008;35:1426–30.

26. Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken). 2010;62:965–9. DOI: https://dx.doi.org/10.1002/acr.20155.

27. Saber TP, Ng CT, Renard G, et al. Remission in psoriatic arthritis: is it possible and how can it be predicted? Arthritis Res Ther. 2010;12(3):94–8. DOI: https://dx.doi.org/10.1186/ar3021.

28. Eder L, Chandran V, Shen H, et al. Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis? Ann Rheum Dis. 2010;69:2160–4. DOI: https://dx.doi.org/10.1136/ard.2010.129726.

29. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68:1387–94. DOI: https://dx.doi.org/10.1136/ard.2008.094946.

30. Kavanaugh AF, Ritchlin CT. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol. 2006;33:1417–21.

31. Sarzi-Puttini P, Santandrea S, Boccasini L, et al. The role of NSADI in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exper Rheumatol. 2001;19 Suppl 22:17–20.

32. Ritchlin CT. Therapies for psoriatic enthesopathy. A systematic review. J Rheumatol. 2006;33:1435–8.

33. Abu-Shakra M, Gladman DD, Thorne JC, et al. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol. 1995;22:241–5.

34. Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate andpsoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol. 2009;60:824–37. DOI: https://dx.doi.org/10.1016/j.jaad.2008.11.906.

35. Salvarani C, Macchioni P, Olivieri I, et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol. 2001;28:2274–82.

36. Madan V, Griffiths CE. Systemic cyclosporine and tacrolimus in dermatology. Dermatol Ther. 2007;20:239–50. DOI: https://dx.doi.org/10.1111/j.1529-8019.2007.00137.x.

37. Fernandez Sueiro JL, Juanola Roura X, Canete Crespillo JD, et al. Consensus statement of the Spanish Society of Rheumatology on the management of biologic therapies in psoriatic arthritis. Rheumatol Clin. 2011;7:179–88.

38. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained beneits of inliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the inliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005;52(4):1227–36. DOI: https://dx.doi.org/10.1002/art.20967.

39. Gladman DD, Sampalis JS, Illouz O, Guerette B. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study. J Rheumatol. 2010;37(9):1898–906. DOI: https://dx.doi.org/10.3899/jrheum.100069.

40. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty- four-week efficacy and safety results of a randomized, placebocontrolled study. Arthritis Rheum. 2009;60(4): 976–86. DOI: https://dx.doi.org/10.1002/art.24403.

41. McInnes I, Kavanaugh A, Gottlieb A, et al. Ustekinumab in patients with active psoriatic arthritis: Results of the phase 3, multicenter, double-blind, placebo-controlled PSUMMIT I study. Ann Rheum Dis. 2012;71:107–10. DOI: https://dx.doi.org/10.1136/annrheumdis-2012-eular.1841.

42. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373:633–40. DOI: https://dx.doi.org/10.1016/S0140-6736(09)60140-9.

43. Fonseca JE, Lucas H, Canhao H, et al. Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases candidates for therapy with tumor necrosis factor alpha inhibitors: March 2008 update. Acta Reumatol Port. 2008;33:77–85.

44. Van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54:2136–46. DOI: https://dx.doi.org/10.1002/art.21913.

45. Inman RD, Davis JC, Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58:3402–12. DOI: https://dx.doi.org/10.1002/art.23969.

46. Papp K, Langley R, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double- blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675–8. DOI: https://dx.doi.org/10.1016/S0140- 6736(08)60726-6.

47. McInnes I, Kavanaugh A, Gottlieb A, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780–9. DOI: https://dx.doi.org/10.1016/S0140-6736(13)60594-2.

48. Atteno M, Peluso R, Costa L, et al. Comparison of effectiveness and safety of ifliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol. 2010;29(4):399–403. DOI: https://dx.doi.org/10.1007/s10067-009-1340-7.

49. Glintborg B, Ostergaard M, Dreyer L, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum. 2011;63:382–90. DOI: https://dx.doi.org/10.1002/art.30117.

50. Dougados M, Combe B, Braun J, et al. A randomized, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. Ann Rheum Dis. 2010;69:1430–5. DOI: https://dx.doi.org/10.1136/ard.2009.121533.

51. Heilwell PS. Therapies for dactylitis in psoriatic arthritis. A systematic review. J Rheumatol. 2006;33:1439–41.

52. Van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70:905–8. DOI: https://dx.doi.org/10.1136/ard.2011.151563.

53. Salvarany C, Boiardi L, Macchioni P, et al. Multidisciplinary focus on Cyclosporin A. J Rheumatol. 2009;83:52–5.

1. Gladman DD, Stafford-Brady F, Chang CH, et al. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol. 1990;17:809-12.

2. McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford). 2003;42:778-83. doi: 10.1093/rheumatology/keg217

3. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3:55-78. doi: 10.1016/0049-0172(73)90035-8

4. Zias J, Mitchell P. Psoriatic arthritis in a fifth-century Judean Desert monastery. Am J Phys Anthropol. 1996;101:491-502. doi: 10.1002/(SICI)1096-8644(199612)101:4<491::AIDAJPA4>3.0.CO;2-Z

5. Moll JM, Haslock I, Macrae IF, Wright V. Associations between ankylosing spondylitis, psoriatic arthritis, Reiter’s disease, the intestinal arthropathies, and Behcet’s syndrome. Medicine (Baltimore). 1974;53:343-64. doi: 10.1097/00005792-19740900000002

6. Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016;374:2563-74. doi: 10.1056/NEJMra1406182

7. Taylor WJ, Gladman DD, Helliwell PS, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665-73. doi: 10.1002/art.21972

8. Olivieri I, Padula A, D’Angelo S, Cutro MS. Psoriatic arthritis sine psoriasis. J Rheumatol. 2009; Suppl 83:28-9. doi: 10.3899/jrheum.090218

9. Eder L, Haddad A, Rosen CF, et al. The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study. Arthritis Rheum. 2016;68:915-23. doi: 10.1002/art.39494

10. Villani AP, Rouzaud M, Sevrain M, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis. J Am Acad Dermatol. 2015;73:242-8. doi: 10.1016/j.jaad.2015.05.001

11. Чамурлиева МН, Логинова ЕЮ, Коротаева ТВ. Выявляемость псориатического артрита у больных псориазом в дерматологической и ревматологической клинике. Современная ревматология. 2016;10(4):47-50 [Chamurlieva MN, Loginova EYu, Korotaeva TV. Detection rates of psoriatic arthritis in patients with psoriasis in a dermatology and rheumatology clinic. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2016;10(4):47-50 (In Russ.)]. doi: 10.14412/1996-7012-2016-4-47-50

12. Michelsen B, Fiane R, Diamantopoulos AP, et al. A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. PLoS One. 2015;10(4):e0123582. doi: 10.1371/journal.pone.0123582

13. Kotsis K, Voulgari PV, Tsifetaki N, et al. Anxiety and depressive symptoms and illness perceptions in psoriatic arthritis and associations with physical health-related quality of life. Arthritis Care Res (Hoboken). 2012;64:1593-601. doi: 10.1002/acr.21725

14. Tillett W, Shaddick G, Askari A, et al. Factors influencing work disability in psoriatic arthritis: first results from a large UK multicentre study. Rheumatology (Oxford). 2015;54:157-62. doi: 10.1093/rheumatology/keu264

15. Arumugam R, McHugh NJ. Mortality and causes of death in psoriatic arthritis. J Rheumatol. 2012;89 Suppl:32-5. doi: 10.3899/jrheum.120239

16. Buckley C, Cavill C, Taylor G, et al. Mortality in psoriatic arthritis – a singlecenter study from the UK. J Rheumatol. 2010;37:2141-4. doi: 10.3899/jrheum.100034

17. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic Arthritis. N Engl J Med. 2017;376:957-70. doi: 10.1056/NEJMra1505557

18. Mease PJ. Psoriatic Arthritis: update on pathophysiology, assessement and management. Ann Rheum Dis. 2011;70 Suppl:77-84. doi: 10.1136/ard.2010.140582

19. Love TJ, Zhu Y, Zhang Y, et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis. 2012;71:1273-7. doi: 10.1136/annrheumdis-2012-201299

20. Коротаева ТВ. Псориатический артрит: клиника, диагностика, патогенез, лечение, маркеры кардиоваскулярного риска. Москва: НПО «Медиа-Графика»; 2013. 309 с. [Korotaeva TV. Psoriaticheskii artrit: klinika, diagnostika, patogenez, lechenie, markery kardiovaskulyarnogo riska [Psoriatic arthritis: clinic, diagnosis, pathogenesis, treatment, markers of cardiovascular risk]. Moscow: NPO «Media-Grafika»; 2013. 309 p.]. ISBN 978-5-905541-02-5.

21. Khan M, Schentag C, Gladman DD. Clinical and radiological changes during psoriatic arthritis disease progression. J Rheumatol. 2003;30:1022-6.

22. Gladman DD, Ziouzina O, Thavaneswaran A, Chandran V. Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era. J Rheumatol. 2013;40:1357-9. doi: 10.3899/jrheum.130163

23. Brockbank JE, Stein M, Schentag CT, Gladman DD. Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis. 2005;64:188-90. doi: 10.1136/ard.2003.018184

24. Kehl AS, Corr M, Weisman MH. Review: enthesitis: new insights into pathogenesis, diagnostic modalities, and treatment. Arthritis Rheum. 2016;68:312-22. doi: 10.1002/art.39458

25. Stoll ML, Zurakowski D, Nigrovic LE, et al. Patients with juvenile psoriatic arthritis comprise two distinct populations. Arthritis Rheum. 2006;54:3564-72. doi: 10.1002/art.22173

26. Colbert RA. Classification of juvenile spondyloarthritis: enthesitisrelated arthritis and beyond. Nat Rev Rheumatol. 2010;6:477-85. doi: 10.1038/nrrheum.2010.103

27. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64 Suppl 2:14-7. doi: 10.1136/ard.2004.032482

28. Chandran V, Barrett J, Schentag NC, et al. Axial Psoriatic Arthritis: update on a longterm prospective study. J Rheumatol. 2009;36;2744-50. doi: 10.3899/jrheum.090412

29. Sieper J, van der Heijde D, Landewe R, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis International Society (ASAS). Ann Rheum Dis. 2009;68:784-8. doi: 10.1136/ard.2008.101501

30. Kane D, Pathare S. Early psoriatic arthritis. Rheum Dis Clin North Am. 2005;31(4):641-57. doi: 10.1016/j.rdc.2005.07.009

31. Qureshi AA, Husni ME, Mody E. Psoriatic arthritis and psoriasis: need for a multidisciplinary approach. Semin Cutan Med Surg. 2005;24:46-51. doi: 10.1016/j.sder.2005.01.006

32. Prey S, Paul C, Bronsard V, et al. Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24 Suppl 2:31-5. doi: 10.1111/j.1468-3083.2009.03565.x

33. Gottlieb A, Korman N, Gordon K, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851-64. doi: 10.1016/j.jaad.2008.02.040

34. Mease PJ. Assessing the impact of psoriatic arthritis on patient function and quality of life: lessons learned from other rheumatologic conditions. Semin Arthritis Rheum. 2009;38:320-35. doi: 10.1016/j.semarthrit.2008.01.003

35. Raychaudhuri SK, Chatterjee S, Nguyen C, et al. Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord. 2010;8:331-4. doi: 10.1089/met.2009.0124

36. Li W-Q, Han J-L, Chan TA. Psoriasis and psoriatic arthritis and increased risk of incedent Crohn’s disease in US women. Ann Rheum Dis. 2013 Jul;72(7):1200-5. doi: 10.1136/annrheumdis2012-202143

37. Ogdie A, Schwartzman S, Husni ME. Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol. 2015;27:118-26. doi: 10.1097/BOR.0000000000000152

38. Gossec L, Smolen J, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71(1):4-12. doi: 10.1136/annrheumdis-2011-200350

39. Mease PJ. Assessment tools in psoriatic arthritis. J Rheumatol. 2008;35:1426-30.

40. Gladman DD, Inman RD, Cook RJ, et al. International spondyloarthritis interobserver reliability exercise – the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol. 2007;34:1740-5.

41. Nell-Duxneuner VP, Stamm TA, Machold KP, et al. Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. Ann Rheum Dis. 2010;69:546-9. doi: 10.1136/ard.2009.117945

42. Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology. 2003;42(2):244-57. doi: 10.1093/rheumatology/keg072

43. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68:1387-94. doi: 10.1136/ard.2008.094946

44. Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis. 2010;70:272-7. doi: 10.1136/ard.2010.129379

45. Helliwell PS, Fitzgerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis. 2013;72:98691. doi: 10.1136/annrheumdis-2012-201341

46. Saber TP, Ng CT, Renard G, et al. Remission in psoriatic arthritis: is it possible and how can it be predicted? Arthritis Res Ther. 2010;12(3):94-8. doi: 10.1186/ar3021

47. Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken). 2010;62:965-9. doi: 10.1002/acr.20155

48. Kavanaugh AF, Ritchlin CT. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol. 2006;33:1417-21.

49. Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheum. 2016;68:1060-71. doi: 10.1002/art.39573

50. Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75:499-510. doi: 10.1136/annrheumdis2015-208337

51. Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis. 2005;64 Suppl 2:ii74-ii77. doi: 10.1136/ard.2004.030783

52. Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford). 2012;51:1368-77. doi: 10.1093/rheumatology/kes001

53. Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2004;50:1939-50. doi: 10.1002/art.20253

54. Mease PJ. Biologic therapy for psoriatic arthritis. Rheum Dis Clin North Am. 2015;41:723-38. doi: 10.1016/j.rdc.2015.07.010

55. Weitz JE, Ritchlin CT. Ustekinumab: targeting the IL-17 pathway to improve outcomes in psoriatic arthritis. Expert Opin Biol Ther. 2014;14:515-26. doi: 10.1517/14712598.2014.890587

56. McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-ofconcept trial. Ann Rheum Dis. 2014;73:349-56. doi: 10.1136/annrheumdis-2012-202646

57. Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76:79-87. doi: 10.1136/annrheumdis-2016-209709

58. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73:1020-6. doi: 10.1136/annrheumdis-2013205056

59. Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a sixmonth, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 2011;63:939-48. doi: 10.1002/art.30176